Xue Wang

2 papers in the library · 9 citations · publishing 2025

Papers

Psychedelics and Pro-Social Behaviors: A Perspective on Autism Spectrum Disorders

ACS Pharmacology & Translational Science February 10, 2025 Xue Wang, Cong Lin, Xiaohui Wang 5 citations

Psychedelics like LSD, psilocybin, and MDMA may enhance pro-social behaviors in people with autism spectrum disorders by altering brain circuits involved in social cognition. The viewpoint discusses potential mechanisms underlying these effects, such as increased neuroplasticity and changes in serotonin receptor activity. While direct evidence in ASD populations is limited, the authors suggest that these compounds could offer new therapeutic avenues for improving social interaction and communication deficits. The paper calls for further research to explore the safety and efficacy of psychedelic-assisted therapy for autism, emphasizing the need for controlled clinical trials.

DOI: 10.1021/acsptsci.5c00034 Mental health treatment Psychedelics Autism spectrum disorders Neuroscience +1

Psychedelics and the Gut Microbiome: Unraveling the Interplay and Therapeutic Implications.

ACS Chemical Neuroscience July 9, 2025 Xue Wang, Fan Jun, Cong Lin et al. 4 citations

Classic psychedelics and the gut microbiome influence each other through 5-HT2A receptor signaling, neuroplasticity, and microbial metabolism. Psychedelics may alter the composition of gut bacteria, while the microbiome can affect how well these compounds work. The authors propose using microbiome-informed approaches, such as probiotics or dietary changes, to tailor and improve psychedelic treatments for mental health conditions.

DOI: 10.1021/acschemneuro.5c00418 Full text Psilocybin Gut microbiome Gut−brain axis Inflammation +11